Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
VANCOUVER, British Columbia, April 25, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom Burton & Co. Healthcare Investor Conference in Toronto. Chief Executive Officer Mary Szela is scheduled to present on Monday, May 1, 2017 at 10:00 a.m. EDT.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
